Phase II, Dose Finding Study of GTx-758
Public ClinicalTrials.gov record NCT01393119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Open-label, Loading and Maintenance Dose Finding Study of GTx-758 in Men With Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.
Study identification
- NCT ID
- NCT01393119
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 80 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2011
- Primary completion
- Nov 30, 2012
- Completion
- Nov 30, 2012
- Last update posted
- Apr 21, 2024
2011 – 2012
United States locations
- U.S. sites
- 21
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GTx Investigative Site | Glendale | Arizona | 85306 | — |
| GTx Investigative Site | Phoenix | Arizona | 85032 | — |
| GTx Investigative Site | La Mesa | California | 91942 | — |
| GTx Investigative Site | San Bernardino | California | 92404 | — |
| GTx Investigative Site | Aventura | Florida | 33180 | — |
| GTx Investigative Site | Bradenton | Florida | 34205 | — |
| GTx Investigative Site | St. Petersburg | Florida | 33710 | — |
| GTx Investigative Site | Tampa | Florida | 33607 | — |
| GTx Investigative Site | Roswell | Georgia | 30076 | — |
| GTx Investigative Site | Jeffersonville | Indiana | 47130 | — |
| GTx Investigative Site | Shreveport | Louisiana | 71106 | — |
| GTx Investigative Site | Annapolis | Maryland | 21401 | — |
| GTx Investigative Site | Towson | Maryland | 21204 | — |
| GTx Investigative Site | Hamilton | New Jersey | 08690 | — |
| GTx Investigative Site | Albany | New York | 12208 | — |
| GTx Investigative Site | Oneida | New York | 13421 | — |
| GTx Investigative Site | Syracuse | New York | 13210 | — |
| GTx Investigative Site | Concord | North Carolina | 28025 | — |
| GTx Investigative Site | Cincinnati | Ohio | 45212 | — |
| GTx Investigative Site | Columbus | Ohio | 43220 | — |
| GTx Investigative Site | Bala-Cynwyd | Pennsylvania | 19004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01393119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2024 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01393119 live on ClinicalTrials.gov.